Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

U.S. Acellular Dermal Matrices Market, By Origin (Human Dermis, Porcine Dermis, Bovine Dermis), By Application (Acute Wounds (Burns, Trauma, Cancers, Infections) Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, Others), Reconstruction Procedures (Abdominal Wall Procedures, Breast Procedures, Orthopedic Procedures, Others), By Place of Setting (Hospitals, Ambulatory Surgical Centers, Office Based) is estimated to be valued at US$ 2,057.3 Mn in 2020 and is expected to exhibit a CAGR of 10.6% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Increasing number of surgeries is expected to boost growth of the U.S. acellular dermal matrices market over the forecast period. For instance, according to the American Society of Plastic Surgeons 2019 report, around 299,715 breast augmentation and 2,721,469 soft tissue filler procedures were performed in the U.S. in 2019.

Moreover, various strategies such as new product launches, acquisitions, and agreements are adopted by market players in order to retain their market position, and this is expected to drive the market growth over the forecast period. For instance, In October 2016, Acelity, a global advanced wound care and regenerative medicine company, lunched its ALLODERM SELECT DUOTM Regenerative Tissue Matrix in the U.S. ALLODERM Regenerative Tissue Matrix is the nation’s leading biological tissue matrix for soft tissue reinforcement in breast reconstruction procedures..

U.S. Acellular Dermal Matrices Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 32 million infected individuals in the U.S. as of May 24 2021. COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Moreover, increasing focus on development of novel supply chain tools will help to combat the effect of COVID-19 on the suppliers operating in the market. Due to this, manufacturers come to know a complete information of where raw materials are coming from for manufacturing. Furthermore, the U.S.-China trade tensions had already elevated country of origin and landed-cost considerations, particularly for companies with outsourced or semi-outsourced supply chains. This has added some extra logistic costs for manufacturing. Now, increasing focus on development of novel supply chain tools, which will help to combat the effect of covid-19 on the suppliers operating in the market have been introduced. These supply chain tools will support resilience strategies and compliance related to a range of import and export matters, such as conforming to child labor laws, and others. Furthermore, players operating in the U.S. acellular dermal matrices market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials for manufacturing matrices due to irregularities in transportation facility.

Browse 9 Market Data Tables and 17 Figures spread through 188 Pages and in-depth TOC on ‘U.S. Acellular Dermal Matrices Market’-  Forecast to 2027, U.S. Acellular Dermal Matrices Market, By Origin (Human Dermis, Porcine Dermis, Bovine Dermis), By Application (Acute Wounds (Burns, Trauma, Cancers, Infections), Chronic Wounds(Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, Others), Reconstruction Procedures (Abdominal Wall Procedures, Breast Procedures, Orthopedic Procedures, Others), By Place of Setting (Hospitals, Ambulatory Surgical Centers, Office Based)

https://www.coherentmarketinsights.com/market-insight/us-acellular-dermal-matrices-market-4442

Moreover, rising number of surgeries is a factor which is expected to drive the market growth over the forecast period. For instance, according to 2019 report published by American Society of Plastic Surgeons, in the U.S. around 3,592,576 reconstructive procedures and 4,553,896 cosmetic procedures were performed in hospitals in 2019.

Key Takeaways of the U.S. Acellular Dermal Matrices Market:

  • The U.S. acellular dermal matrices market is expected to exhibit a CAGR of 10.6% during the forecast period owing to increasing product launch and approval which is expected to drive the market growth over the forecast period. For instance, in January 2019, Cell Constructs I, LLC received 510(k) premarket approval from the U.S. Food and Drug Administration for its ProgenaMatrix indicated for dry and exuding partial and full thickness wounds such as pressure (stage I-IV) and venous stasis ulcers, ulcers caused by mixed vascular etiologies, diabetic ulcers, donor sites and grafts, first and second degree burns, superficial injuries, cuts, abrasions and surgical wounds.
  • Among application, reconstruction procedures segment accounted for the largest market share in U.S. acellular dermal matrices market over the forecast period. Moreover, increasing novel product launch is expected to drive the segment growth. For instance, in March 2019, Fidia Pharma USA Inc., launched its NuDYN, amniotic membrane-derived allograft for orthopedic and other applications.
  • On the basis place of setting, ambulatory surgical centers segment is estimated to exhibit higher CAGR in the U.S. Acellular Dermal Matrices Market over the forecast period due to increasing number of patient’s visits to ambulatory surgical centers. For instance, according to the report published by Medicare Payment Policy (MedPac), in 2017, around 5,500 ASCs (Ambulatory surgical center services) treated 3.4 million fee-for-service patients in the U.S.
  • Major players operating in the U.S. Acellular Dermal Matrices Market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, Marine Polymer Technologies, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.